Answers are grounded in this paper and cite their sources.
Experimental findings reveal that anti-dopaminergic agents reduce angiogenic markers in a diabetic eye model, suggesting future therapeutic applications.
Key messages What is known • Anti-dopaminergic agents (metoclopramide (MCP), trimethobenzamide (TMB), and domperidone (DOM)) are used for diabetic gastroparesis, but their effects on diabetic eye are not well studied. What is new • These drugs do not affect intraocular pressure or tear production in diabetic rats. • They increase retinal prolactin receptor expression and reduce VEGF and CD31 immunoreactivity, indicating modulation of angiogenesis-related markers in the diabetic retina. • These findings may encourage future research to explore the potential role of prolactin-elevating antidopaminergic agents in diabetic retinopathy.
No takes yet. Share an insight, caveat, or question.
Peker et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: